Instituto Bioclon
| Private | |
| Industry | Biomedicine |
| Founded | 1990 |
| Headquarters | Mexico City, Mexico |
| Services | Antivenom research and development |
Number of employees | not known |
| Parent | Silanes Laboratories |
| Website | http://www.bioclon.com.mx |
About
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms.
Operations
The Instituto Bioclon is located in Mexico City, Mexico and has a Certificación Internacional de Buenas Prácticas de Manufactura (International Certificate for Good Manufacturing Practices) which was granted to Bioclon by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos, (INVIMA) (National Food and Drug Monitoring Institute), of the Ministerio de la Protección Social (Secretary of Social Protection) of Colombia, as well as by COFEPRIS, in Mexico.
Products
- Coralmyn® - coral snake antivenom[1]
- Antivipmyn® - pit viper antivenom
- Antivipmyn® TRI – Central and South American snakes
- Antivipmyn® Africa – African snakes
- Alacramyn® - scorpion antivenom
- Reclusmyn® - brown recluse antivenom
- Aracmyn® - black widow antivenom
The Bioclon Institute is the only Mexican company that has obtained an "orphan drug" status from the Food and Drug Administration (FDA) of the United States for three of its products.
References
- ↑ Deborah Silverstein; Kate Hopper (5 September 2014). Small Animal Critical Care Medicine. Elsevier Health Sciences. p. 916. ISBN 978-0-323-24352-0.